DENVER, Feb. 21 /PRNewswire-FirstCall/ -- Myogen, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that the abstract describing the effects of darusentan in patients with resistant hypertension was selected for presentation at ACC.06, the 55th Annual Scientific Session of the American College of Cardiology, which will be held March 11-14, 2006 at the Georgia World Congress Center in Atlanta, Georgia.
The abstract highlights the results of a recent trial evaluating the antihypertensive effect of darusentan in patients with hypertension despite full (optimized) doses of three antihypertensive medications including a diuretic, a condition referred to as resistant hypertension. The Phase 2b dose-ranging trial evaluated darusentan compared to placebo in 115 patients with resistant hypertension.
Henry Black, M.D., will present "Darusentan Antihypertensive Effect in Patients with Resistant Hypertension" at the General Hypertension Poster Session, Presentation Number 915-208, Sunday, March 12, 2006, between 9:00 a.m. and 10:00 a.m. (Eastern). Dr. Black is Professor and Chairman, Department of Preventive Medicine at Rush University Medical Center and a principal investigator for the darusentan Phase 2b trial.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension and darusentan for the treatment of patients with resistant hypertension. The Company also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen's website at www.myogen.com.
Safe Harbor Statement
This press release contains forward-looking statements that involve significant risks and uncertainties, including summary statements relating to the results of the Company's darusentan Phase 2b clinical trial. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release.
Results from and designs of clinical trials, including the Company's darusentan Phase 2b trial, are not necessarily predictive of future clinical results or trial designs. Top line results may not be confirmed upon full analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of the Company's product candidates, including darusentan, may be discovered upon further analysis of trial data and upon review and analysis of additional trial data, including data from the Company's anticipated Phase 3 trials of darusentan in resistant hypertension. If the Company's product candidates do not meet safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and the Company will not be able to market them. Even if the Company's product candidates meet safety and efficacy endpoints, regulatory authorities may not approve them, the Company may not be able to successfully market them, or the Company may face post-approval problems that require the withdrawal of its product from the market. The Company's results may be affected by its effectiveness at managing its financial resources, its ability to successfully develop and market its product candidates, its ability to obtain and enforce patent protection for its products, competition from other biotechnology and pharmaceutical companies, difficulties or delays in manufacturing its products, and regulatory developments involving current and future products. Delays in initiating or conducting clinical trials, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors, could adversely affect the Company's financial position and prospects. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue one or more of its drug development or discovery research programs. Myogen is at an early stage of development and may not ever have any products that generate significant revenue.
Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of Myogen's Form 10-K for the year ended December 31, 2004 and Myogen's reports on Form 10-Q and Form 8-K. It is Myogen's policy to only update or reconfirm its public guidance by issuing a press release or filing a periodic or current report with the Securities and Exchange Commission. All information in this press release is as of February 21, 2006. Myogen undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in the Company's expectations.
Myogen, Inc.CONTACT: Derek K. Cole, Director, Investor Relations of Myogen, Inc.,+1-303-464-3986, derek.cole@myogen.com
Web site: http://www.myogen.com/
